DexCom enters the week after a 29% one-month rally with an unusual split: analysts are lifting targets in its wake, yet options traders just registered their most defensive positioning of the year — a tension worth watching heading into July earnings.
The sharpest signal this week is in options. The put/call ratio jumped to 1.02 on June 9, well above its 20-day average of 0.86 and running more than three standard deviations above the mean — the highest defensive skew in the past year. That single-day move stands out because the prior three weeks showed the ratio anchored between 0.81 and 0.90. Whether this represents fresh hedging after a 29% one-month run or positioning ahead of the July 23 earnings date, the options market is clearly more cautious than usual. Short interest tells a calmer story. Bears cover: the short position has fallen roughly 7% on the week to 4.3% of free float, about 16.9 million shares, continuing a decline from a local peak near 19 million shares in mid-May. Borrow conditions remain loose — availability is running at 3,275% of short interest, near the upper end of its 52-week range and well clear of any squeeze territory, with cost to borrow a negligible 0.47%. Shorts are not pressed here.
Analyst activity this week has been uniformly bullish, and the pace of upgrades has accelerated. TD Cowen raised its target from $75 to $95 on June 10, maintaining Buy, while Mizuho lifted from $75 to $85 the day before. Earlier in the week, Stifel moved from $85 to $90. All three kept positive ratings. The Street consensus stands at a mean target of around $84.67 — already below the current price of $78.19 but with TD Cowen's $95 now pulling the high end of the range materially higher. Bulls point to DexCom's expanding international penetration in continuous glucose monitoring, growing reimbursement tailwinds, and the potential for non-intensive Type 2 diabetes patients becoming a significant new market. Bears — Barclays holds an Underweight with a $64 target — argue that competitive pressure from Abbott and others, alongside a premium valuation, leaves limited room for error. The EV/EBITDA multiple has risen roughly 1% over the past seven days to near 16.8x, with the price-to-book up 27% over 30 days, reflecting the extent of the re-rating already in the price.
Insider activity over the past month adds a layer of context. The CCO, Jon Curtis Coleman, sold roughly 17,000 shares across three transactions in late May and early June at prices between $71.90 and $74.13. Executive Chairman Kevin Sayer sold nearly 27,000 shares at $72.00 on May 21 — a $1.9 million transaction. The CFO and President/COO also sold small tranches on May 22. Net insider activity over 90 days is a positive 167,000 shares, but recent selling at $60–$74 levels — well below today's $78.19 — suggests executives have not been chasing the rally. That pattern is not alarming on its own but sits in contrast to the bullish analyst tone.
The earnings history is mildly supportive. The most recent Q1 result on May 14 produced a next-day gain of 5.2% and a five-day gain of 22.8%, reflecting a strong revenue beat of $679 million against expectations. The prior event on April 30 also produced a positive 6.6% next-day move. Two positive reactions in a row have likely contributed to the current positioning — both the stock's rebound and the elevated put/call ratio as investors reassess risk ahead of the July 23 Q2 print.
With the stock up 6.5% on the week and analysts still hiking targets, the July 23 earnings date becomes the next key test — specifically whether DexCom can confirm that the Q1 beat was the start of a trend rather than a one-quarter event.
See the live data behind this article on ORTEX.
Open DXCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
